MBX Biosciences, Inc. Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Steve Hoerter
- Full Time Employees
- 63
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11711 N. Meridian Street Carmel IN United States of America 46032
- IPO Date
- Sep 13, 2024
- CIK
- 0001776111
- Website
- mbxbio.com
- Similar Companies
- Business
- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Carmel, Indiana, develops novel precision endocrine peptide (PEP) therapies utilizing its proprietary PEP platform to treat endocrine and metabolic disorders including hypoparathyroidism, post-bariatric hypoglycemia, and obesity; its lead product candidate, canvuparatide (MBX 2109), a long-acting parathyroid hormone (PTH) peptide prodrug delivered via once-weekly subcutaneous injection, advances in Phase 2 Avail trial for chronic hypoparathyroidism following positive Phase 1 data showing sustained serum calcium elevation, low peak-to-trough ratios, and good tolerability, with Phase 3 initiation planned for 2026; imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist, progresses in Phase 2 for post-bariatric hypoglycemia after Phase 1 pharmacokinetics supporting weekly dosing; MBX 4291, a potent GLP-1/GIP co-agonist prodrug, enters Phase 1 for obesity targeting once-monthly administration with preclinical weight loss comparable to tirzepatide at lower concentrations, alongside additional preclinical programs in rare and prevalent endocrine diseases. The company operates primarily in the United States with a discovery pipeline leveraging advanced chemical modifications, programmable prodrug technologies, and fatty acylation for optimized potency, selectivity, half-life, and tolerability. Recent developments include its initial public offering and upsized follow-on offering in September 2024 raising over $200 million gross proceeds for a cash position of $391.7 million as of September 30, 2025 funding operations into 2029; positive topline Phase 2 Avail results in Q3 2025; a $63.5 million Series C financing in August 2024; executive appointments such as Chief Medical Officer Salomon Azoulay in June 2024 and Chief Scientific Officer Steven Prestrelski in 2023; FDA IND clearance for MBX 1416 in 2023; and $115 million Series B financing in 2022.
Company News
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Microbix Reports Results for Q3 Fiscal 2026
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High After Analyst Upgrade
MBX Biosciences (NASDAQ:MBX) Hits New 12-Month High – Here’s Why
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey
MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
Microbix Schedules Release of Results for Q2 Fiscal 2026